Reviews/Omega-3 Fatty Acids/Omega-3 for childhood attention-deficit/hyperactivity disorder
Neuro · OMEGA-NEURO-03 · v2
Across the trials collected here, most well-designed studies that compared omega-3 against a dummy pill found no real improvement in children's ADHD symptoms. The largest such trial [2] actually saw the placebo group improve more than the omega-3 group. A few studies reported something positive, but these were either small, measured a narrow slice of behaviour, or came from looking at blood levels rather than the head-to-head comparison the trial was built to test. One study [6] had no dummy-pill group at all, so its improvements could simply reflect children getting better over time. The panel concluded that the controlled evidence does not back a general claim that omega-3 improves ADHD symptoms.
The best-powered placebo-controlled trials are null or negative on their primary ADHD endpoints: [2] (N=162) found the placebo group's ADHD-RS-IV fell more than the active group (-19% vs -9.7%, p = 0.039), [3] (N=160) found matched responder rates (46.3% omega-3 vs 45.6% placebo), [1] found no effect on parent- and teacher-rated behavior, and [4] (N=74, underpowered) found inattention reductions of -1.57 vs -2.90 placebo (p = 0.33). [10] found no significant difference between treatments, with benefit appearing only as correlations between erythrocyte EPA+DHA and attention (r = -.540, p < .001). The positive signals are limited: [5] improved parent-rated attention but equally in typically developing controls, and [8] (N=60) showed a borderline impulsivity reduction (P = .049). [6] (N=90) lacked a placebo arm. The contested point: The division is between the randomised primary-outcome results, which are null-to-negative, and the weaker positive signals drawn from secondary measures, correlational blood-level analyses [10], a non-specific effect seen in controls too [5], and a borderline subdomain endpoint [8]. Whether those scattered positives reflect a real narrow effect or chance and multiple comparisons is the open question.
All 10 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Omega-3 Fatty Acids, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The majority of included placebo-controlled RCTs ([1],[2],[3],[4],[10]) show no significant benefit on their pre-specified primary ADHD outcomes, and the best-powered ([2], N=162) found placebo superior to active treatment.
Positive findings rest on secondary or non-randomised analyses: [10]'s benefit is correlational rather than the randomised contrast, and [8]'s impulsivity effect is borderline (p=.049, N=60), raising chance and multiple-comparison concerns.
Where it remains uncertain. The only positive signals are a non-specific attention gain seen equally in controls [5], a borderline impulsivity reduction [8], and correlational associations [10] rather than randomised contrasts.
Aleatory
[8]'s impulsivity effect (N=60, P = .049) and [4]'s underpowered early-stopped design (N=74) sit close to chance, so random variation cannot be separated from a true effect.
Epistemic
Trials differ in EPA:DHA ratio, added GLA [3], phospholipid vector [4], and duration (8 weeks to 12 months), so it is unknown whether any specific regimen works even if the broad claim fails.
Inferential
[10]'s positive findings are associations between blood EPA+DHA and attention, not the randomised treatment contrast, which showed no significant difference.
The load-bearing papers from a corpus of 10, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Null for behavioural ADHD symptoms despite biomarker increase.
“improved working memory function, but had no effect on other cognitive measures and parent- and teacher-rated behavior in the study population”
Panel auditInternal validity: high · scope of inference: Children 6-12 with DSM-IV ADHD; behavioural symptom ratings and cognitive measures over 16 weeks.Key limitations: working-memory gain is cognition, not a core ADHD symptom rating · single trial population
No benefit on primary inattention outcome.
“No superiority of Omega-3/6 supplement to placebo was observed on the primary outcome (ADHD-RS-inattention score) after the first 6-months, with 46.3% of responders in the Omega-3/6 group and 45.6% in the placebo group”
Panel auditInternal validity: high · scope of inference: Children 6-12 with mild inattentive-type ADHD, Omega-3/6 combination product.Key limitations: mild inattentive subtype only · a total-score improvement noted but not clinically significant
No improvement (underpowered) in comorbid epilepsy population.
“The reduction after 12 weeks of treatment in the inattention subscore of the ADHD-IV scale was -1.57 in the PS-Omega3 group, and -2.90 in the placebo group (p = 0.33, α = 5%).”
Panel auditInternal validity: low · scope of inference: Children >6 and <16 with epilepsy-associated ADHD, phospholipid-conjugated EPA/DHA formulation.Key limitations: underpowered, stopped early · epilepsy comorbidity population · specific PS-Omega3 formulation
Largest placebo-controlled RCT (N=162) shows placebo superior on primary outcome — directly contradicts the claim.
“The total ADHD-RS-IV score reduction was greater in the placebo group than in the DHA-EPA group: -19 (-26, -12) % and -9.7 (-16.6, -2.9) %, respectively, p = 0.039.”
Panel auditInternal validity: high · scope of inference: Children 6-15 with established ADHD, 3-month DHA-EPA supplementation.Key limitations: conclusion frames population as mild/moderate symptoms · two severe adverse events in the active arm
4 of 10 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Multiple independent, mostly double-blind RCTs fail to show a reliable benefit on pre-specified ADHD outcomes, so the general claim of improvement is not supported.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Adequately powered trial of a single standardised formulation. The corpus pools divergent EPA:DHA ratios, added GLA [3] and phospholipid vectors [4], confounding any uniform conclusion. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A pre-registered, double-blind, placebo-controlled RCT of one fixed EPA-dominant dose in uncomplicated pediatric ADHD, powered on a single ADHD-RS primary endpoint.
Open question: Does a single standardised EPA-dominant formulation and dose improve primary ADHD-symptom scores in uncomplicated pediatric ADHD? Why it is still open: Every included trial used a different formulation, dose or duration, and the best-powered ([2]) tested a mixed regimen in mild ADHD with a negative result.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19